Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease

This is the authors' abstract. We don't add key points for this paper.

Minimal residual disease (MRD) was measured in samples from 5 patients with multiple myeloma (MM), 5 patients with B-cell chronic lymphocytic leukemia (B-CLL), and 4 patients with T-cell lymphoproliferative disorders (T-CLPD) by detecting three different levels of malignant cells (approximately 20-30, 40-60, and 80-200).Results are presented as the mean of 5 independent trials.The CV was calculated as (standard-deviation/mean) x 100.